{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.06","upperLimit":"85.40","value":"73.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"CCyR was defined as 0% 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or fluorescence in situ hybridization (FISH). Loss of cytogenetic burden of disease (via FISH or classic karyotyping) was required to reach CCyR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"OG000","title":"Pemigatinib 13.5 mg"}],"paramType":"NUMBER","populationDescription":"Full Efficacy-Evaluable Population. Confidence intervals were calculated based on the exact method for binomial distribution.","reportingStatus":"POSTED","timeFrame":"up to 2513 days (120 21-day treatment cycles)","title":"Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}